Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Journal:

The BMJ

Published:

2025-06-05

DOI:

10.1136/bmj-2025-085680

Affiliations:

17

Authors:

19

Go to article

Institutions	Authors	Share
Sichuan Kelun Pharmaceutical Co., Ltd., China	3.000000	0.16
State Key Laboratory of Oncology in South China, SYSUCC, China	2.000000	0.11
First Affiliated Hospital, ZZU, China	1.000000	0.05
Shandong Cancer Hospital, China	1.000000	0.05
National Engineering Research Centre of Targeted Biologics, China	1.000000	0.05
Shengjing Hospital of China Medical University, China	1.000000	0.05
The First Affiliated Hospital of Nanchang University, China	1.000000	0.05
Sichuan Cancer Hospital, China	1.000000	0.05
Fujian Cancer Hospital, China	1.000000	0.05
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.05
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.05
Hunan Cancer Hospital, China	1.000000	0.05
The First Affiliated Hospital of Henan University of Science and Technology, China	1.000000	0.05
Shanxi Cancer Hospital, China	1.000000	0.05
Cancer Hospital of Yunnan Province, China	1.000000	0.05
Henan Cancer Hospital, ZZU, China	0.500000	0.03
Henan Academy of Innovations in Medical Science, China	0.500000	0.03

Interested in Oncology and Carcinogenesis?